DNDi aims to deliver:

  • Safe, effective, and orally administered drugs to replace current first-line sleeping sickess treatments, and to simplify current case management.
  • The goal is to develop two drugs effective for both stage-1 and 2, and both subspecies of the parasite.

 

The current sleeping sickness portfolio includes:

 Research

Research

SCYX-1330682 & SCYX-1608210 Oxaboroles

Development

Development

Acoziborole (SCYX-7158)
Fexinidazole

 Implementation

Implementation

NECT – Nitfurtimox-Eflornithine Combination Therapy

 

For more details on each project, see DNDi‘s Global Portfolio